Genetics of neurofibromatosis 1 and the NF1 gene

Journal of Child Neurology

Volumn 17, Issue 8, 2002, Pages 562-570

  Viskochil, David ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; NEUROFIBROMIN; RAS PROTEIN;

ADOLESCENT; ADULT; AUTOSOMAL DOMINANT DISORDER; CLINICAL FEATURE; COMPLICATION; CONTROLLED STUDY; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN GENETICS; NEUROFIBROMATOSIS; NOONAN SYNDROME; PENETRANCE; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0036700983     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380201700804     Document Type: Review

References (49)

1. Korf B: Diagnostic outcome in children with multiple café-au-lait spots. Pediatrics 1992;90:924-927.
2. Friedman JM: Neurofibromatosis 1: Clinical manifestations and diagnostic criteria. J Child Neurol 2002; 17:548-554.
3. Easton DF, Ponder MA, Huson SM, et al: An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): Evidence for modifying genes. Am J Hum Genet 1993;53:305-313.
4. Easton DF: Genotype-phenotype relationships in neurofibromatosis type 1, in Upadhyaya M, Cooper DN (eds): Neurofibromatosis Type 1: From Genotype to Phenotype. Oxford, BIOS Scientific Publishers, 1998, 167-174.
5. Carey J, Viskochil D: Neurofibromatosis type 1: A model condition for the study of the molecular basis of variable expressivity in human disorders. Am J Med Genet 1999;89:7-13.
6. Kayes LM, Riccardi VM, Burke W, et al: Large de novo DNA deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and dysmorphism. J Med Genet 1992;29:686-690.
7. Kayes L, Burke W, Riccardi VM, et al: Deletions spanning the neurofibromatosis 1 gene: Identification and phenotype of five patients. Am J Hum Genet 1994;54:424-436.
8. Tonsgard J, Yelavarthi K, Cushner S, et al: Do NF1 gene deletions result in a characteristic phenotype? Am J Med Genet 1997;73: 80-86.
9. Wu B-L, Austin MA, Schneider GH, et al: Deletion of the entire NF1 gene detected by FISH: Four deletion patients associated with severe manifestations. Am J Med Genet 1995;59:528-535.
10. Wu B-L, Schneider GH, Korf BR: Deletion of the entire NF1 gene causing distinct manifestations in a family. Am J Med Genet 1997;69:98-101.
11. Cnossen MH, van der Est MN, Breuning MH, et al: Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1? Hum Mutation 1997;9:458-464.
12. Leppig KA, Kaplan P, Viskochil D, et al: Familial neurofibromatosis 1 microdeletions: Cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am J Med Genet 1997;73:197-204.
13. Upadhyaya M, Cooper D: The mutational spectrum in neurofibromatosis 1 and its underlying mechanisms, in Upadhyaya M, Cooper DN (eds): Neurofibromatosis Type 1: From Genotype to Phenotype. Oxford: BIOS Scientific Publishers, 1998, 65-88.
14. Riccardi VM, Eichner JE: Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. Baltimore: Johns Hopkins University Press,1986.
15. Ruggieri M, Huson SM: The clinical and diagnostic implications of mosaicisim in the neurofibromatoses. Neurology 2001;56:1433-1443.
16. Colman S, Rasmussen S, Ho V, et al: Somatic mosaicism in a patient with neurofibromatosis type 1. Am J Hum Genet 1996;58: 484-490.
17. Ainsworth P, Chakraborty P, Weksberg R: Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion. Hum Mutat 1997;9:452-457.
18. Wu B-L, Boles R, Yaari H, et al: Somatic mosaicism for deletion of the entire NF1 gene identified by FISH. Hum Genet 1997;99: 209-213.
19. Lazaro C, Gaona A, Lynch M, et al: Molecular characterization of the breakpoints of a 12-kb deletion in the NF1 gene in a family showing germ-line mosaicism. Am J Hum Genet 1995;57: 1044-1049.
20. Tinschert S, Naumann I, Stegmann E, et al: Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000;8:455-459.
21. Allanson JE, Hall JG, Van Allen MI: Noonan phenotype associated with neurofibromatosis. Am J Med Genet 1985;21:457-462.
22. Watson GH: Pulmonary stenosis, café-au-lait spots, and dull intelligence. Arch Dis Child 1967;42:303-307.
23. Allanson JE, Upadhyaya M, Watson G, et al: Watson syndrome: Is it a subtype of type 1 neurofibromatosis? J Med Genet 199 1;28: 752-756.
24. Carey JC: Neurofibromatosis-Noonan syndrome. Am J Med Genet 1998;75:263-264.
25. Carey J, Stevenson D, Ota M, et al: Is there an NF/Noonan syndrome? Part 2: Documentation of the clinical and molecular aspects of an important family. Proc Greenwood Genet Cent 1998;17:52-53.
26. Tassabehji M, Strachan T, Sharland M, et al: Tandem duplication within a neurofibromatosis type 1 (NF1) gene exon in a family with features of Watson syndrome and Noonan syndrome. Am JHum Genet 1993;53:90-95.
27. Tartaglia M, Mehler EL, Goldberg R, et al: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-468.
28. Brunner HG, Hulsebos T, Steijlen PM, et a]: Exclusion of the neurofibromatosis 1 locus in a family with inherited café-au-lait spots. Am J Med Genet 1993;46:472-474.
29. Charrow J, Listernick R, Ward K: Autosomal dominant multiple café-au-lait spots and neurofibromatosis-1: Evidence of non-linkage. Am J Med Genet 1993;45:606-608.
30. Abeliovich D, Gelman-Kohan Z, Silverstein S, et al: Familial café-au-lait spots: A variant of neurofibromatosis type 1. J Med Genet 1995;32:985-986.
31. Pulst SM, Riccardi VM, Fain P, et al: Familial spinal neurofibromatosis: Clinical and DNA linkage analysis. Neurology 1991;41: 1923-1925.
32. Poyhonen M, Leisti E-L, Kytola S, et al: Hereditary spinal neurofibromatosis: A rare form of NF1? JMed Genet 1997;34:184-187.
33. Ars E, Kruyer H, Gaona A, et al: A clinical variant of neurofibromatosis type 1: Familial spinal neurofibromatosis with a frameshift mutation in the NF1 gene. Am J Hum Genet 1988;62:834-841.
34. Viskochil D: The structure and function of the NF1 gene: Molecular pathophysiology, in Friedman JM, Gutmann DH, MacCollin M, Riccardi VM (eds): Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, 3rd ed. Baltimore and London, Johns Hopkins University Press. 1999, 119-141.
35. Hajra A, Martin-Gallardo A, Tarle S, et al: DNA sequences in the promoter region of the NF1 gene are highly conserved between human and mouse. Genomics 1994;21:649-652.
36. Mancini DB, Singh SM, Archer TY, et al: Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SPI transcription factors. Oncogene 1999; 18: 4108-4119.
37. Horan MP, Cooper DN, Upadhyaya M: Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. Hum Genet 2000;107:33-39.
38. Skuse GR, Cappione AJ, Sowden M, et al: The neurofibromatosis type 1 messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res 1996;24:478-485.
39. Mukhopadhyay D, Anant S, Lee RM, et al: C → U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am Hum Genet 2002; 70:38-50.
40. Viskochil D: Neurofibromatosis 1. Am J Med Genet 1999;89:v-viii.
41. Lopez-Correa C, Brems H, Lazaro C, et al: Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. Hum Mutat 1999;14:387-393.
42. Dorschner MO, Sybert VP, Weaver M, et al: NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 2000;9:35-46.
43. Jenne DE, Tinschert S, Reimann H, et al: Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 2001;69:516-527.
44. Lopez-Correa C, Dorschner M, Brenis H, et al: Recombination hotspot in NF1 microdcrodeletion patients. Hum Mol Genet 2001; 10: 1387-1392.
45. Mikol D, Gulcher J, Stefansson K: The oligodendrocyte myeline glycoprotein belongs to a distinct family of proteins and contains the HNK-I carbohydrate. J Cell Biol 1990; 110:471-480.
46. Habib AA, Gulcher JR, Hognason T, et al: The Omgp gene, a second growth suppressor within the NF1 gene. Oncogene 1998; 16:1525-1531.
47. Purandare S, Huntsman-Breidenbach H, Li Y, et al: Identification of neurofibromatosis 1 (NF1) homologous loci by direct sequencing, fluorescence in situ hybridization and PCR amplification of somatic cell hybrids. Genomics 1995;30:476-485.
48. Hulsebos T, Bijlereld E, Riegman P, et al: Identification and characterization of NF1-related loci on human chromosomes 22, 14, and 2. Hum Genet 1996;98:7-11.
49. Regnier V, Meddeb M, Lecointre G, et al: Emergence and scattering of multiple neurofibromatosis (NF1)-related sequences during hominoid evolution suggest a process of pericentromeric interchromosomal transposition. Hum Mol Genet 1997;6:9-16.